WesBanco Bank’s Pacira BioSciences PCRX Stock Holding History

WesBanco Bank’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,503	Closed	-$429K	–	595
2023 Q1	$429K	Hold	10,503	–	–	0.02%	445
2022 Q4	$406K	Buy	+10,503	New	+$511K	0.02%	444

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WesBanco Bank's PCRX Position: Q2 2023 in Review

WesBanco Bank sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 10,503 shares — an estimated $429K sold.

WesBanco Bank first reported a position in PCRX in Q4 2022 and held it in 2 quarters. The position peaked at $429K in Q1 2023. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

WesBanco Bank reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
WesBanco Bank sold 10,503 Pacira BioSciences shares in Q2 2023, an estimated $429K.
WesBanco Bank first reported a position in Pacira BioSciences in Q4 2022 and held it in 2 quarters.
WesBanco Bank's Pacira BioSciences position peaked at $429K in Q1 2023.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on WesBanco Bank's 13F filing for Q2 2023, filed 13 Jul 2023.